Clinical Experience with Posaconazole in Patients with Invasive Mucormycosis: a Case Series

Michelle M. González-Ramos, Jorge Bertrán-Pasarell, Humberto Guiot, Ruth Soto, Jorge Santana, Rosana Amador, Ana Conde


Posaconazole (POS) is approved for prophylaxis of Aspergillus and Candida infections in immunocompromised patients and for the treatment of oropharyngeal candidiasis. Data is limited as step-down therapy after treatment with amphotericin B (AMB). Four cases with refractory mucormycosis who had a favorable response after a change in antifungal therapy to POS are presented. In these four patients, POS demonstrated to be an effective therapeutic option in the management of refractory mucormycosis. Further studies should be conducted to define its role, whether as a single agent or as adjuvant therapy in combination with AMB.

Full Text:


Published by the University of Puerto Rico Medical Sciences Campus
Founded in 1982